Malaysia Biotech CCM Duopharma Announces Expansion Plans
This article was originally published in PharmAsia News
Malaysia's CCM Duopharma Biotech says it plans to spend $23.1 million over the next three years to expand its plant to accommodate its growth expectations. In addition to expanding its production capacity, CCMD also plans to buy new machinery, upgrade amenities and improve its warehousing and waste-water treatment facilities. The result, it says, should be increased capacity for producing injectables, liquids and ampule-packing capacity. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.